CN113016719B - 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 - Google Patents
一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 Download PDFInfo
- Publication number
- CN113016719B CN113016719B CN201911343700.XA CN201911343700A CN113016719B CN 113016719 B CN113016719 B CN 113016719B CN 201911343700 A CN201911343700 A CN 201911343700A CN 113016719 B CN113016719 B CN 113016719B
- Authority
- CN
- China
- Prior art keywords
- synuclein
- phenotype
- rbd
- animal
- inducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000019355 Synuclein Human genes 0.000 title claims abstract description 31
- 108050006783 Synuclein Proteins 0.000 title claims abstract description 31
- 230000001575 pathological effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000007958 sleep Effects 0.000 title abstract description 18
- 206010000117 Abnormal behaviour Diseases 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 36
- 241001465754 Metazoa Species 0.000 claims abstract description 31
- 230000001939 inductive effect Effects 0.000 claims abstract description 22
- 230000036285 pathological change Effects 0.000 claims abstract description 21
- 231100000915 pathological change Toxicity 0.000 claims abstract description 21
- 238000010171 animal model Methods 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 16
- 230000006698 induction Effects 0.000 claims abstract description 12
- 230000002146 bilateral effect Effects 0.000 claims abstract description 7
- 238000002474 experimental method Methods 0.000 claims description 33
- 210000002569 neuron Anatomy 0.000 claims description 31
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 11
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 11
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 claims description 9
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 claims description 9
- 230000003542 behavioural effect Effects 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- 230000001744 histochemical effect Effects 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 241000700159 Rattus Species 0.000 claims description 5
- 210000001142 back Anatomy 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 2
- 238000007489 histopathology method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 abstract description 13
- 230000007170 pathology Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 238000010899 nucleation Methods 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 210000004940 nucleus Anatomy 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000003523 substantia nigra Anatomy 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 208000032859 Synucleinopathies Diseases 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241001573498 Compacta Species 0.000 description 3
- 208000025535 REM sleep behavior disease Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003479 dental cement Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000009958 sewing Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000006650 Overbite Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及一种在非人受试动物中诱导可向帕金森表型转归的快动眼睡眠行为障碍(RBD)表型的方法,该方法包括1)向非人受试动物的单侧或双侧脑桥被盖背外侧下核(SLD)立体定向注射能够诱导突触核蛋白病理变化的物质;2)评估所述非人受试动物的RBD表型的诱导情况;3)在所述RBD动物中评估帕金森表型的诱导情况。本发明还涉及一种突触核蛋白病理性RBD模型的制备方法。本发明提出了通过向SLD核团立体定向注射可诱导突触核蛋白病理的预制纤维体(PFFs),借助于该纤维体“播散‑成核”的病理诱导特性从而构建可向帕金森表型转归的小鼠RBD模型,预期该模型可为未来研究中阐明RBD的病因、发病机制、帕金森转归及研发有效的阻断药物提供重要的动物模型基础。
Description
技术领域
本发明涉及医学和生物技术领域。具体而言,本发明涉及基于脑桥被盖背外侧下核(SLD)突触核蛋白病理特征的可向帕金森表型转归的动物快动眼睡眠行为障碍(RBD)模型的制备方法。
背景技术
作为帕金森病重要的运动前症状,快动眼睡眠行为障碍(RBD)最早在运动症状出现前10年即可出现[1],并且对原发性RBD病人持续随访发现随访10-15年时约有80-90%的病人转化为突触核蛋白病[2]。对原发性RBD病人的神经影像和尸体解剖研究也提示:该阶段病人已有纹状体多巴胺转运体功能降低、中脑黑质多巴胺能神经元丢失、蓝斑下核(subcoeruleus nucleus)MRI-SWI序列低信号及核团内部路易病理形成[3-5]。据此,从临床病理学角度来说:与帕金森病相同,原发性RBD也可归属为突触核蛋白病家族成员[6]。因而,如能在此阶段采取措施积极干预延缓或阻断RBD向帕金森病的转归不仅会对帕金森病的发病具有重要的早期预警意义,也将从根本上改变现有的帕金森病治疗格局。
成功构建能准确反映疾病外在症状表现和内在病理本质的动物模型是对临床疾病开展基础与临床研究的前提。对RBD发病机制的认识和动物模型的构建也经历了一个漫长的过程:20世纪50年代法国科学家Michel Jouvet首次发现电凝破坏脑桥被盖特定区域可诱导实验动物快动眼睡眠期(REM)睡眠期出现极类似于梦境演绎样的行为(dream-enactment behavior),因而,由此做出“完整的脑桥被盖(intact pontine tegmentum)是REM睡眠发生和其间肌张力松弛状态维持的前提条件”的推测[7]。此后,经过一系列的深入研究,人们对于该“脑桥被盖REM睡眠调节区”的认识不断加深,最终将该目标核团定位于脑桥被盖背外侧下区并命名为:脑桥被盖背外侧下核(SLD)[8-10]。围绕该核团,研究人员先后使用机械破坏[7]、毒素毁损[11]和核团功能性神经元相关受体、转运体基因敲除或沉默[12-15]的手段诱导实验动物出现程度不等的RBD样行为,从而为本发明方案中提出的制备突触核蛋白病理特征性的RBD动物模型提供了技术可行性支持证据。
然而,以上列举的诸多现有RBD建模方案仍有很大的缺陷:1.早期使用的机械毁破坏和后来的神经毒素毁损法会不可避免地波及周边的脑区和核团,引入诸多不可预测的混杂因素,难以做到单一变量化、精准化,也不能体现RBD突触核蛋白病的病理本质;2.新兴的针对REM睡眠调控环路上关键受体、转运体的基因突变或基因沉默策略,虽可选择性地靶向操纵特定区域特定类型的神经元从而实现精准化及微创化,但该造模方法没有突触核蛋白病理因素的参与,也不能体现RBD突触核蛋白病的病理本质;3.上述RBD模型构建方案无论是机械破坏、毒素毁损还是REM环路受体、转运体基因沉默策略无一例外都是在短时间内甚至即时诱导动物出现RBD样行为,因而并不符合RBD这一慢性进行性退变的突触核蛋白病的病理生理特征。
新近出现的预制纤维体(PFFs)被证实在体[16]或离体[17]干预均可诱导内源性ɑ-synuclein单体发生错误折叠、聚集形成寡聚体、原纤维、纤维进而聚合成路易小体和路易突起(Lewy body&neurite),随细胞裂解释放的纤维被邻近神经元摄取后可诱导同样的病理变化,由此引发类似于朊蛋白样(prion-like)的“成核-播散(seeding-propagation)”反应[18]。据此,我们推测:向实验动物脑桥被盖SLD核团定向注射PFFs后可在局部诱发突触核蛋白病理变化诱导动物出现RBD样行为,借助于PFFs“成核-播散”的朊蛋白样病理传播特性可介导黑质-纹状体系统发生渐进性突触核蛋白病理变化进而模拟出帕金森样表型,由此成功构建以SLD核团突触核蛋白病理为基础可向帕金森表型转归的RBD动物模型。
参考文献
1.Lorraine V Kalia,Anthony E Lang.Parkinson’s disease[J].The Lancet,2015,386(9996):896-912.
2.Dauvilliers Y,Schenck C H,Postuma R B,et al.REM sleep behaviourdisorder[J].Nature Reviews Disease Primers,2018,4(1):1-16.
3.Albin R L,Koeppe R A,Chervin R D,et al.Decreased striataldopaminergic innervation in REM sleep behavior disorder[J].Neurology,2000,55(9):1410-1412.
4.García-Lorenzo D,Longo-Dos Santos C,Ewenczyk C,et al.The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders inParkinson’s disease[J].Brain,2013,136(7):2120-2129.
5.Boeve B F,Dickson D W,Olson E J,et al.Insights into REM sleepbehavior disorder pathophysiology in brainstem-predominant Lewy body disease[J].Sleep medicine,2007,8(1):60-64.
6.B,Stefani A,Videnovic A.Idiopathic REM sleep behaviourdisorder and neurodegeneration—an update[J].Nature Reviews Neurology,2018,14(1):40.
7.Roussel B,Pujol J F,Jouvet M.Effets des lésions du tegmentumpontique sur lesétats de sommeil chez le rat[J].Arch.ital.Biol.,1976,114:188-209.
8.Boissard R,Gervasoni D,Schmidt M H,et al.The rat ponto-medullarynetwork responsible for paradoxical sleep onset and maintenance:a combinedmicroinjection and functional neuroanatomical study[J].European Journal ofNeuroscience,2002,16(10):1959-1973.
9.Fort P,Bassetti C L,Luppi P H.Alternating vigilance states:newinsights regarding neuronal networks and mechanisms[J].European Journal ofNeuroscience,2009,29(9):1741-1753.
10.Luppi P H,Clément O,Sapin E,et al.The neuronal network responsiblefor paradoxical sleep and its dysfunctions causing narcolepsy and rapid eyemovement(REM)behavior disorder[J].Sleep medicine reviews,2011,15(3):153-163.
11.Lu J,Sherman D,Devor M,et al.A putative flip–flop switch forcontrol of REM sleep[J].Nature,2006,441(7093):589.
12.Brooks P L,Peever J H.Impaired GABA and glycine transmissiontriggers cardinal features of rapid eye movement sleep behavior disorder inmice[J].Journal of Neuroscience,2011,31(19):7111-7121.
13.Krenzer M,Anaclet C,Vetrivelan R,et al.Brainstem and spinal cordcircuitry regulating REM sleep and muscle atonia[J].PloS one,2011,6(10):e24998.
14.Valencia Garcia S,Libourel P A,Lazarus M,et al.Geneticinactivation of glutamate neurons in the rat sublaterodorsal tegmentalnucleus recapitulates REM sleep behaviour disorder[J].Brain,2016,140(2):414-428.
15.Valencia Garcia S,Brischoux F,Clément O,et al.Ventromedial medullainhibitory neuron inactivation induces REM sleep without atonia and REM sleepbehavior disorder[J].Nature Communications,2018,9.
16.Luk K C,Kehm V,Carroll J,et al.Pathologicalα-synucleintransmission initiates Parkinson-like neurodegeneration in nontransgenic mice[J].Science,2012,338(6109):949-953.
17.Volpicelli-Daley L A,Luk K C,Lee V M Y.Addition of exogenousα-synuclein preformed fibrils to primary neuronal cultures to seed recruitmentof endogenousα-synuclein to Lewy body and Lewy neurite–like aggregates[J].Nature protocols,2014,9(9):2135.
18.Masuda-Suzukake M,Nonaka T,Hosokawa M,et al.Prion-like spreadingof pathologicalα-synuclein in brain[J].Brain,2013,136(4):1128-1138.
发明内容
基于RBD发生的睡眠调控环路和PFFs的突触核蛋白病理诱导特性,本发明提出通过向SLD核团立体定向注射具有突触核蛋白病理诱导特性的ɑ-突触核蛋白PFFs,借助于该纤维体“播散-成核”的病理诱导特性从而构建可向帕金森表型转归的小鼠RBD模型,预期该模型将为未来研究中阐明RBD的病因、发病机制、帕金森转归及研发有效的阻断药物提供重要的动物模型基础。
具体地,本发明包括但不限于如下项目所公开的技术方案。
项目1.一种在非人受试动物中诱导可向帕金森表型转归的RBD表型的方法,该方法包括
1)向非人受试动物的单侧或双侧SLD立体定向注射能够诱导突触核蛋白病理变化的物质;
2)评估所述非人受试动物的RBD表型的诱导情况;
3)在所述RBD表型动物中评估帕金森表型的诱导情况。
项目2.项目1所述的方法,其中所述能够诱导突触核蛋白病理变化的物质是预制纤维体(PFFs),优选ɑ-突触核蛋白寡聚体或多聚体。
项目3.项目1或2所述的方法,其中向非人受试动物的单侧或双侧SLD核团立体定向注射能够诱导突触核蛋白病理变化的物质。
项目4.项目2所述的方法,其中突触核蛋白预制纤维体是人源化或鼠源化α突触核蛋白多聚体。
项目5.项目1-4任一项所述的方法,其中通过视频-多导睡眠记录方法、组织病理学方法、或行为学评估方法评估所述非人受试动物的RBD表型的诱导。
项目6.项目5所述的方法,其中所述组织病理学方法包括对脑桥被盖层面做NeuN、pS129-ɑ-突触核蛋白组织化学染色,并观察各层面SLD核团神经元丢失及病理性ɑ-突触核蛋白聚集情况。
项目7.项目5所述的方法,其中所述行为学评估方法包括帕金森相关的运动表型评估方法,包括转棒实验、悬挂实验。
项目8.项目1-7任一项所述的方法,其中所述非人受试动物包括非人哺乳动物,例如非人灵长类动物,例如啮齿动物,例如猴、马、牛、犬、猫、小鼠、大鼠和猪等。
项目9.一种用于在非人受试动物中诱导可向帕金森表型转归的RBD表型的试剂盒,所述试剂盒包含能够在非人受试动物的SLD核团局部诱导突触核蛋白病理变化的物质。
项目10.项目9所述的试剂盒,其中所述能够诱导突触核蛋白病理变化的物质是预制纤维体(PFFs),优选ɑ-突触核蛋白寡聚体或多聚体。
项目11.项目9-10任一项所述的试剂盒,其还包含注射工具和/或试剂。
项目12.一种可向帕金森表型转归的RBD动物模型的制备方法,其包括用项目1-8任一项的方法中定义的步骤1)至步骤3)制备诱导了RBD表型的动物模型。
在一些实施方案中,本发明提供本文描述的能够诱导突触核蛋白病理变化的物质是预制纤维体(PFFs),优选ɑ-突触核蛋白寡聚体或多聚体作为在制备RBD动物模型和/或用于在非人受试动物中诱导RBD表型的试剂盒中的用途。
在一些实施方案中,所述试剂盒包括容器和在容器上或与容器一起的标签或包装说明书。在一些实施方案中,适合的容器包括,例如,瓶子、小瓶、注射器等。所述容器可以由各种材料如玻璃或塑料制成。容器装有组合物,所述组合物是单独地或与能够诱导突触核蛋白病理变化的物质的神经元的另一种试剂或组合物结合。组合物中至少一种试剂是本文的诱导突触核蛋白病理变化的物质。此外,所述试剂盒可以包含:(a)其中包含组合物的第一容器,其中所述组合物包含诱导突触核蛋白病理变化的物质,如预制纤维体(PFFs),优选ɑ-突触核蛋白寡聚体或多聚体;和(b)其它相关试剂。本发明的试剂盒还可以包括包装说明书,所述包装说明书指明所述组合物可以用于制备RBD动物模型和/或在非人受试动物的SLD核团局部诱导突触核蛋白病理变化。所述试剂盒还可以包括第二或第三容器,所述第二或第三容器包含缓冲剂,如注射用水,磷酸盐缓冲盐水,葡萄糖溶液,还可以包括其他材料,如其他缓冲剂、稀释剂、滤器、针头和注射器。
附图说明
图1.PFFs制备流程示意图(ɑ-syn:ɑ-突触核蛋白;rpm:每分钟转速)。
图2.PFFs超声前后超微形态对比及纤维长度分布统计图a.超声前;b.超声后。
图3.立体定向注射位点示意图。
图4.PBS和PFFs组小鼠睡眠时相及RBD发作时EEG/EMG波形图(红色箭头示REM期频繁肌电活动),3m.p.i.:术后3个月。
图5.PBS和PFFs组小鼠SLD核团NeuN和pS129-ɑ-突触核蛋白(pS129-ɑ-synuclein)组织化学染色图及定量分析与对照组小鼠相比,PFFs处理组小鼠SLD核团NeuN阳性神经元计数显著减少(a-c),pS129-ɑ-突触核蛋白阳性神经元数目显著增加(d-f),差异具有统计学意义。统计学方法:PBS组vs PFFs组参数比较使用非配对T检验;****p<0.0001。
图6.PBS和PFFs组小鼠的帕金森运动行为学统计分析a.转棒实验;b.悬挂实验;统计学方法:PBS组vs PFFs组参数比较使用非配对T检验;*p<0.05,**p<0.01,****p<0.0001。
图7.PBS和PFFs组小鼠黑质致密部(SNc)TH和pS129-ɑ-突触核蛋白(pS129-AS)组织化学染色图及定量分析与对照组小鼠相比,PFFs处理组小鼠黑质致密部TH阳性神经元计数(a,c)和纹状体多巴胺递质浓度进行性减少(e),pS129-ɑ-突触核蛋白阳性神经元数目显著增加(b,d),差异具有统计学意义。PBS组vs PFFs组参数比较使用Two-way ANOVA plusTukey’s multiple comparison test;**p<0.01,***p<0.001,****p<0.0001,n.s.,无统计学差异。
具体实施方式
以下对本发明的具体实施方式进行详细说明,所描述的各个具体实施方式不是限制性的,并且可以相互组合。
本发明的技术方案可分为五部分:1.PFFs的制备与立体定向注射;2.视频-多导睡眠记录及睡眠数据分析;3.RBD表型的组织病理学验证;4.帕金森表型的行为学评估;5.帕金森表型的生化及组织病理验证。具体分述如下:
1.PFFs的制备与立体定向注射
α突触核蛋白单体在37℃环境下经连续7天涡旋振荡(1000转/分)后超声粉碎,调整浓度至5mg/ml后分装,-80℃冰箱储存;立体定向注射到小鼠双侧SLD核团(800nl/侧),术后恢复10天继续后续实验。
2.视频-多导睡眠记录及睡眠数据分析
睡眠记录前1周埋置电极,恢复7天后开始视频-多导睡眠记录,持续记录7天后解除设备进行睡眠数据分析,结合同步记录视频观察小鼠在REM睡眠期的肌电及行为变化判读RBD行为。
3.RBD表型的组织病理学验证
在预定时间节点麻醉小鼠,灌流固定后取脑、包埋、切片,挑选脑桥被盖层面做NeuN、pS129-ɑ-突触核蛋白组织化学染色,观察各层面SLD区域神经元丢失及病理性α突触核蛋白聚集情况并进行定量分析。
4.帕金森表型的行为学评估
在预定时间节点对各组小鼠进行帕金森相关的运动及非运动表型评估,具体评估项目包括转棒实验、悬挂实验,评估各组小鼠在帕金森相关运动、情绪及认知行为方面有无变化。
5.帕金森表型的生化及组织病理验证
在预定时间节点麻醉小鼠,灌流固定后取脑、包埋、切片,挑选中脑黑质及纹状体层面做TH、pS129-ɑ-突触核蛋白组织化学染色,观察各组小鼠黑质致密部(SNc)、纹状体层面神经元丢失及病理性ɑ-突触核蛋白聚集情况并进行定量分析。
根据上述规划的技术方案,以下结合附图和具体的实施方案对本发明做进一步的说明:
实验1.PFFs的制备和立体定向注射
1.材料及主要试剂
人源ɑ-突触核蛋白单体(PFFs制备专用)购自美国Proteos公司(货号:RP-003);PBS(不含钙、镁)购自上海生工(货号:E607009);BCA蛋白质定量检测试剂盒购自赛默飞世尔科技(Thermo Fisher Scientific,货号:23225);C57BL/6J小鼠购自中国科学院实验动物资源平台;400目电镜铜网购自中镜科仪;2%磷钨酸负染液购自中镜科仪。
2.实验方法
(1)PFFs制备
吸取人源ɑ-突触核蛋白单体加入1.5ml离心管(冰上操作,目测液体澄清透明),离心(4℃,12000rpm,5min)后吸取上清,使用BCA法测蛋白浓度并调整浓度至5mg/ml。密封离心管固定于恒温振荡摇床(Thermo Fisher)上,调节温度(37℃)、转速(1000rpm)后开启摇床。连续振荡7天后,关闭摇床,取出离心管(目测液体浑浊)(见图1)。
(2)超声粉碎及分装
离心(4℃,12000rpm,5min)后吸取上清,使用接触式超声粉碎仪(上海左乐仪器)粉碎纤维体,调节功率为10%,工作模式为2s脉冲,开-关,共计100s,冰上操作,超声粉碎后目测液体变澄清。按20ul/管的规格分装纤维体后储存于-80℃冰箱(见图1)。
(3)PFFs电镜形态学验证
分别取适量超声前后的PFFs经PBS稀释(1:20)后,以移液枪缓慢滴加到400目电镜铜网上,自然晾干后滴加2%磷钨酸液(PH 6.5)负染1min后120KV生物型透射(Tecnai)电镜观察纤维形态(见图2)。
(4)立体定向注射
选取8-10周龄C57BL/6J小鼠(18-22g),随机分为两组:PFFs组及PBS组。异氟烷气麻(2-3%)后固定于立体定向注射仪(瑞沃德生命科技)上,备皮、切开、分离、调标、钻孔后缓慢下针至目标深度,开启微量进样器缓慢泵入PFFs(800nl,10min)至双侧SLD核团(AP/ML/DV:-5.20/±0.75/-4.10mm)(见图3)。对照组注射等量PBS,注射完毕后停针10min后缓慢退针,生物胶封闭颅骨钻孔、缝皮后送回恢复笼,注意术后保温促进苏醒。
2.实验结果
对超声粉碎前后PFFs的电镜超微形态对比可见:前者呈长条纤维缠结状;后者为长短不一的短棒状(见图2)。PFFs和PBS注射入双侧脑桥被盖SLD核团(AP:-5.20mm)(见图3)。
实验2.视频-多导睡眠记录及睡眠数据分析
1.实验材料及仪器设备
骨科胶水、牙科水泥购自上海玉研仪器;排针、排线等电极制备原材料购自铭泰鑫电子;数据采集软件Spike 2购自英国CED公司;睡眠数据解析软件SleepSign购自日本Kissei Comtec公司。
2.实验方法
(1)EEG/EMG记录电极埋置
将待记录PFFs和PBS组小鼠异氟烷气麻(2-3%)后固定于立体定向注射仪(瑞沃德生命科技)上,备皮、切开、分离后分别在右侧额叶(AP/ML:+1.50/-0.80mm)和顶叶皮层(AP/ML:+1.50/-1.00mm)钻孔后埋置EEG记录电极螺丝,深度以紧贴硬脑膜表面为宜,EMG记录电极则插入颈下斜方肌,然后以牙科水泥固定电极于颅骨表面,缝皮后送回恢复笼,注意术后保温促进苏醒。
(2)视频-多导睡眠记录
睡眠记录电极埋置术后恢复7天,将待记录小鼠转移至记录笼连接睡眠记录设备适应3天后开始记录,睡眠记录时开启视频监测系统同步录像记录小鼠在睡眠-觉醒时段内的行为。
(2)睡眠数据及RBD行为分析
睡眠记录结束后导出数据,对照同步记录视频,使用SleepSign软件解析小鼠在清醒(wake,W)、慢波睡眠(slow wave sleep,SWS)及快动眼睡眠(REM,R)状态下的肌电强度变化、有无RBD样行为表现。
3.实验结果
视频-多导睡眠记录分析提示:相比于PBS组小鼠,PFFs注射3个月后(3m.p.i)可诱导小鼠出现REM期肌电活跃(见图4),同步视频监测发现小鼠在此期表现出频繁的头、四肢及躯干无意识运动。
实验3.RBD表型的组织病理学验证
1.材料及主要试剂
PBS缓冲液(1×)购自上海生工(货号:E607008);多聚甲醛粉剂购自Sigma-Aldrich(货号:158127);NeuN一抗购自Abcam公司(货号:ab104224);pS129-ɑ-突触核蛋白一抗购自Abcam公司(货号:ab51253);生物素化山羊抗兔二抗购自Vector Laboratories公司(货号:BA-1000);生物素化马抗小鼠二抗购自Vector Laboratories公司(货号:BA-2000);DAB组化显色试剂盒套装购自Vector Laboratories公司(货号:SK-4100/PK-6100);苏木素染液购自Vector Laboratories公司(货号:H-3401)。
2.实验方法
(1)麻醉、灌流、固定、组织切片
PFFs或PBS注射3个月后,给予小鼠过量麻醉药物后经心脏依次泵入4℃PBS缓冲液和4%多聚甲醛固定液,取脑经蔗糖梯度脱水后OCT胶包埋速冻,冰冻切片机(Leica)连续切片。
(2)免疫组化染色
挑选脑桥被盖层面切片,经3%H2O2封闭内源性过氧化物酶后,NeuN和pS129-ɑ-突触核蛋白一抗孵育24h(4℃),相应生物素化二抗室温孵育2h后以DAB法显色,待目标信号出现后入PBS及时终止反应。显色结束后根据需要进行苏木素细胞核负染。
(3)SLD核团神经元及pS129病理阳性神经元计数
定位脑桥被盖SLD核团分别计数NeuN阳性和pS129-ɑ-突触核蛋白阳性神经元,其中pS129-ɑ-突触核蛋白阳性神经元定义为:苏木素细胞核显色可见前提下,神经元胞体轮廓或突起内出现pS129-ɑ-突触核蛋白阳性显色点。分别计数、统计SLD核团内神经元及pS129病理阳性神经元。
3.实验结果
相较于PBS对照组,PFFs组小鼠SLD核团NeuN阳性神经元计数显著减少(见图5,a-c);与之相反,该核团pS129-ɑ-突触核蛋白阳性神经元计数显著增加(见图5,d-f)。因此,该发现为PFFs处理后小鼠的RBD样行为提供了组织病理学层面的佐证。
实验4.帕金森表型的行为学评估
1.实验材料及仪器设备
转棒仪购自美国Med-Associates公司;ANY-maze动物行为分析系统购自美国Stoeling公司。
2.实验方法
(1)转棒实验
转棒实验主要用来评估动物四肢的运动协调功能。将小鼠放置在转棒上,转棒初始速度为4rpm,实验开始后转棒将均匀加速至40rpm,历时300s,记录从实验开始到动物跌落的时间。正式开始实验前需对动物进行两天的适应性训练,每只动物每天训练3次,每次5min,次间相隔30min。第三天开始正式实验时,每只动物测试3次,次间相隔30min,3次测试的平均值即为一次测试的实验结果。
(2)悬挂实验
将小鼠放置于饲养笼笼盖上,轻轻晃动使其抓稳后迅速倒置,开始计时,记录其跌落的延迟时间。每只小鼠测试3次,次间相隔15min,3次测试的平均值即为一次测试的实验结果。
3.实验结果
在各行为测试时点(1m.p.i.,3m.p.i.,5m.p.i.&8m.p.i.),与PBS对照组相比,PFFs处理组小鼠运动功能(转棒实验、悬挂实验)呈渐进性下降趋势(图6),这与黑质-纹状体系统的进行性退变相一致。
实验5.帕金森表型的组织病理学验证
1.材料及主要试剂
PBS缓冲液(1×)购自上海生工(货号:E607008);多聚甲醛粉剂购自Sigma-Aldrich(货号:158127);TH一抗购自Abcam公司(货号:ab137869);pS129-ɑ-突触核蛋白一抗购自Abcam公司(货号:ab51253);生物素化山羊抗兔二抗购自Vector Laboratories公司(货号:BA-1000);DAB组化显色试剂盒套装购自Vector Laboratories公司(货号:SK-4100/PK-6100);苏木素染液购自Vector Laboratories公司(货号:H-3401);尼氏染液购自碧云天生物科技公司(货号:C0117)。
2.实验方法
(1)麻醉、灌流、固定、组织切片
在预定时间点(1m.p.i.,3m.p.i.,5m.p.i.&8m.p.i.),给予小鼠过量麻醉药物后经心脏依次泵入4℃PBS缓冲液和4%多聚甲醛固定液,取脑后经蔗糖梯度脱水后OCT胶包埋速冻,冰冻切片机(Leica)连续切片。
(2)纹状体单胺类递质检测
在预定时间点(1m.p.i.,3m.p.i.,5m.p.i.&8m.p.i.),给予小鼠过量麻醉药物后经心脏泵入4℃PBS缓冲液后取脑,分离纹状体,称重后加入高氯酸匀浆、离心,取上清后使用高效液相色谱(HPLC)电化学法测量多巴胺(DA)递质浓度。
(3)免疫组化染色
挑选黑质致密部(SNc),经3%H2O2封闭内源性过氧化物酶后,TH和pS129-ɑ-突触核蛋白一抗孵育24h(4℃),生物素化山羊抗兔二抗室温孵育2h后以DAB法显色,待目标信号出现后入PBS及时终止反应。显色结束后根据需要进行苏木素或尼氏染液负染。
(4)黑质致密部TH阳性神经元及pS129病理阳性神经元计数
分别计数中脑黑质致密部(SNc)TH阳性和pS129-ɑ-突触核蛋白阳性神经元,其中pS129-ɑ-突触核蛋白阳性神经元定义为:苏木素细胞核显色可见前提下,神经元胞体轮廓或突起内出现pS129-ɑ-突触核蛋白阳性显色点。分别计数并统计各组SNc内TH阳性神经元及pS129病理阳性神经元数目。
3.实验结果
相较于PBS对照组,PFFs组小鼠黑质TH阳性神经元计数(图7,a,c)及纹状体单胺类递质(多巴胺)浓度(图7,e)呈时间依赖性下降;与之相反,中脑黑质pS129-ɑ-突触核蛋白病理阳性神经元计数呈时间依赖性增加(图7,b,d)。
Claims (8)
1.一种在非人受试动物中诱导可向帕金森表型转归的快动眼睡眠行为障碍(RBD)表型的方法,该方法包括
1)向非人受试动物的单侧或双侧脑桥被盖背外侧下核立体定向注射能够诱导突触核蛋白病理变化的物质;
2)评估所述非人受试动物的RBD表型的诱导情况;
3)在所述RBD表型动物中评估帕金森表型的诱导情况,
其中所述能够诱导突触核蛋白病理变化的物质是人源化或鼠源化α突触核蛋白多聚体,其中所述非人受试动物为小鼠或大鼠。
2.权利要求1所述的方法,其中向非人受试动物的双侧脑桥被盖背外侧下核核团立体定向注射能够诱导突触核蛋白病理变化的物质。
3.权利要求1-2任一项所述的方法,其中通过视频-多导睡眠记录方法、组织病理学方法、或行为学评估方法评估所述非人受试动物的RBD表型的诱导。
4.权利要求3所述的方法,其中所述组织病理学方法包括对脑桥被盖层面做NeuN、pS129-ɑ-突触核蛋白组织化学染色,并观察各层面脑桥被盖背外侧下核核团神经元丢失及病理性ɑ-突触核蛋白聚集情况。
5.权利要求3所述的方法,其中所述行为学评估方法包括帕金森相关的运动表型评估方法,包括转棒实验、悬挂实验。
6.一种用于在非人受试动物中诱导可向帕金森表型转归的RBD表型的试剂盒,所述试剂盒包含能够在非人受试动物的脑桥被盖背外侧下核核团局部诱导突触核蛋白病理变化的物质,其中能够在非人受试动物的脑桥被盖背外侧下核核团局部诱导突触核蛋白病理变化的物质是人源化或鼠源化α突触核蛋白多聚体,其中所述非人受试动物为小鼠或大鼠。
7.一种可向帕金森表型转归的RBD动物模型的制备方法,其包括用权利要求1-5任一项的方法中定义的步骤1)至步骤3)制备诱导了RBD表型的动物模型,其中所述动物模型为小鼠或大鼠动物模型。
8.能够在非人受试动物的脑桥被盖背外侧下核核团局部诱导突触核蛋白病理变化的物质在制备可向帕金森表型转归的RBD动物模型中的应用,其中所述能够在非人受试动物的脑桥被盖背外侧下核核团局部诱导突触核蛋白病理变化的物质是人源化或鼠源化α突触核蛋白多聚体,其中所述非人受试动物为小鼠或大鼠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911343700.XA CN113016719B (zh) | 2019-12-24 | 2019-12-24 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911343700.XA CN113016719B (zh) | 2019-12-24 | 2019-12-24 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113016719A CN113016719A (zh) | 2021-06-25 |
CN113016719B true CN113016719B (zh) | 2022-08-02 |
Family
ID=76451657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911343700.XA Active CN113016719B (zh) | 2019-12-24 | 2019-12-24 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113016719B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113005150A (zh) * | 2019-12-20 | 2021-06-22 | 复旦大学附属华山医院 | 一种新型的动物快动眼睡眠行为障碍模型的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
-
2019
- 2019-12-24 CN CN201911343700.XA patent/CN113016719B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113016719A (zh) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bilimoria et al. | Microglia function during brain development: new insights from animal models | |
Kim et al. | Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury | |
Kharatishvili et al. | Quantitative diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis | |
Garcia et al. | Ventromedial medulla inhibitory neuron inactivation induces REM sleep without atonia and REM sleep behavior disorder | |
Kunkler et al. | Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents | |
Gibbs et al. | Long-term consequences of a prolonged febrile seizure in a dual pathology model | |
Wang et al. | Animal models of epilepsy: a phenotype-oriented review | |
Koh et al. | Non–cell autonomous epileptogenesis in focal cortical dysplasia | |
CN113016719B (zh) | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 | |
Granziera et al. | Long-term monitoring of post-stroke plasticity after transient cerebral ischemia in mice using in vivo and ex vivo diffusion tensor MRI | |
Tharaneetharan et al. | Functional abnormalities of cerebellum and motor cortex in spinal muscular atrophy mice | |
Kou et al. | Transplantation of rat-derived microglial cells promotes functional recovery in a rat model of spinal cord injury | |
Vermoyal et al. | Grey matter heterotopia subtypes show specific morpho-electric signatures and network dynamics | |
Takase et al. | Prenatal freeze lesioning produces epileptogenic focal cortical dysplasia | |
CN113005150A (zh) | 一种新型的动物快动眼睡眠行为障碍模型的制备方法 | |
Li et al. | Intravital imaging of neocortical heterotopia reveals aberrant axonal pathfinding and myelination around ectopic neurons | |
CN112704567A (zh) | 一种确定动物脑桥被盖背外侧下核(sld)解剖功能学边界的实验方法 | |
Mayadali et al. | Saccadic premotor burst neurons and histochemical correlates of their firing patterns in rhesus monkey | |
Maurer et al. | VEGF-D downregulation in CA1 pyramidal neurons exerts asymmetric changes of dendritic morphology without correlated electrophysiological alterations | |
Billing et al. | Synucleinopathy expansion and non-motor symptoms | |
Stewart et al. | PTEN knockout using retrogradely transported AAVs restores locomotor abilities in both acute and chronic spinal cord injury | |
CN116008558B (zh) | 细胞外基质弹性蛋白降解物在制备诊断或延缓神经退行性疾病的产品中的应用 | |
Sarnat | Timing in Morphogenesis of the Developing Nervous System: Relation to Genetic Programming and Exogenous Teratogenesis | |
Li et al. | Learning-dependent LTP and synaptic ultrastructural modification after physical exercise in rats with middle cerebral artery occlusion: relevance for learning and memory | |
Komotar et al. | Deep brain stimulation for obsessive compulsive disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |